A Phase II Study of 131 I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma

Radioimmunotherapy (RIT) is a rare treatment option for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). We investigated the safety and efficacy of I-rituximab in patients with relapsed or refractory marginal zone lymphomas. Patients with pathologically confirmed marginal zone lympho...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical Medicine Insights. Oncology 2023, Vol.17, p.11795549231218082
Hauptverfasser:	Jang, Yoon Jung, Lim, Sang Moo, Lee, Inki, Byun, Byung Hyun, Lim, Ilhan, Kim, Byung Il, Choi, Chang Woon, Lee, Seung-Sook, Yang, Sung Hyun, Na, Im Il, Lee, Hyo-Rak, Shin, Dong-Yeop, Kang, Hye Jin
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!